Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market can be segmented by Service Type - CMO Segment (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, and Secondary Packaging), Research Phase - CRO Segment (Preclinical, Phase I, Phase II, Phase III, and Phase IV), and Geography.

Market Snapshot

Pharmaceutical CDMO Market Size
Study Period: 2020-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.29 %
Pharmaceutical CDMO Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Pharmaceutical CDMO Market was valued at USD 183.62 billion in 2021. It is expected to reach USD 289.64 billion by 2027, registering a CAGR of 7.29% during the forecast period.

  • As a result of the rising demand for generic medicines and biologics, the capital-intensive nature of the business, and the complex manufacturing requirements, many pharmaceutical companies have identified the potential profitability in contracting with a CMO (contract manufacturing outsourcing) for both clinical and commercial stage manufacturing.
  • The most significant factor driving the growth of CMOs in the pharmaceutical industry is the growing need for state-of-the-art processes and production technologies, which have proven significantly effective in meeting regulatory requirements.
  • The pharmaceutical companies have been directing their priorities toward core competency areas. Hence, they prefer not to dispense available resources, expertise, and technology on formulating the final dose of medicines. The increased competition and shrinking profit margins compelled the pharmaceutical companies to revisit their production processes and R&D activities instead of manufacturing the formulated drug to stay competitive in the market.
  • The complexity of the biopharmaceuticals and the highly personalized medical therapies and devices drive the increased complexity in the supply chain operations and lead to increasing reliance on contract manufacturing. Factors such as these are helpful in the proliferation of the CMO market. In March 2021, Fujifilm Diosynth Biotechnologies selected Holly Springs, North Carolina, for its new JPY 200 billion large-scale cell-culture biomanufacturing site. The new facility will provide large-scale cell-culture manufacturing for bulk drug-substance production. The facility is expected to be operational by the spring of 2025.
  • The CMO/CDMO service sector is uniquely positioned to address some of the challenges drug developers face amid the COVID-19 pandemic. This pandemic has impacted multiple aspects of the pharma and biopharma industry, from drug development, clinical trials, supplies, manufacturing to supply chain logistics. However, the drug shortages due to COVID-19 are limited, and they are expected to remain so for the short term due to stockpiles of pharmaceuticals and APIs globally.

Scope of the Report

Contract manufacturing is a form of outsourcing where a manufacturer enters a formal agreement with another manufacturing firm for its parts, products, or components. The manufacturer uses these parts and products in manufacturing its products. The study provides a granular view of the current CMO industry, with a further breakdown of each segment by region.

A contract manufacturing organization (CMO) is an organization that serves the pharmaceutical industry and provides clients with comprehensive services, from drug development to manufacturing. Outsourcing to a CMO allows the pharmaceutical clients to expand their technical resources without increased overhead. The client can manage its internal resources and costs by focusing on its core competencies and high-value projects while reducing or not adding infrastructure or technical staff.

The study provides a granular view of the current CMO industry, with a further breakdown of each segment by region, as listed in the index.

By Service Type CMO Segment
Active Pharmaceutical Ingredient (API) Manufacturing
Finished Dosage Formulation (FDF) Development and Manufacturing
Solid Dose Formulation
Liquid Dose Formulation
Injectable Dose Formulation
Secondary Packaging
By Research Phase CRO Segment
Pre-clinical
Phase I
Phase II
Phase III
Phase IV
By Geography - Global Pharmaceutical CMO
North America
Segmentation by Service Type
Segmentation by Country
United States
Canada
Europe
Segmentation by Service Type
Segmentation by Country
United Kingdom
Germany
France
Italy
Rest of Europe
Asia Pacific
Segmentation by Service Type
Segmentation by Country
China
India
Japan
Australia
Rest of Asia Pacific
Latin America
Segmentation by Service Type
Segmentation by Country
Brazil
Mexico
Argentina
Rest of Latin America
Middle East and Africa
Segmentation by Service Type
Segmentation by Country
United Arab Emirates
Saudi Arabia
South Africa
Rest of Middle East and Africa
By Geography- Global Pharmaceutical CRO
North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Report scope can be customized per your requirements. Click here.

Key Market Trends

Increasing Investment in R&D expected to Drive the Market

  • The United States is the largest market for drugs worldwide and accounts for about half of the R&D expenditure in the pharmaceutical and biotechnology markets. Hence, CMOs play a critical role in this market and have invested in new facilities and technologies to cater to a wide range of outsourcing units. Besides capturing the benefits of a location in Asia through an in-house investment, the companies are also turning to research-based partnerships as a way of high-end sourcing expertise, building drug discovery, and manufacturing investments in Asia. 
  • The Chinese professional manufacturer of drugs for dermatology and anti-tuberculosis, Huapont, is one of the fastest-growing pharmaceutical manufacturers in China, mainly dependent on R&D and market expansion. CRO/CMOs are able to leverage their expertise, owing to their R&D and complex manufacturing capabilities, to fill the needs of the large generic pharmaceutical and biotech companies. 
  • The gradual change in the working principles of the companies in the market led to the shift in pattern, from cost-control to re-emphasis on value-added services. They also allowed their integration into the value chain of companies. The highly fragmented nature of the US pharmaceutical contract manufacturing market, with more than 150 CMOs, results in competition (in terms of price) and drives impacts the revenue of CMOs. 
  • R&D investments, as well as capacity expansions, are expected in the injectable and sterile liquid dose formulations segment. Small biotech firms get access to specialized knowledge and resources, which help them expedite their R&D activities. Greater technological complexity in drug development and greater specificity in targets helped in the average R&D costs, as firms identify drugs with particular molecular characteristics, as opposed to using trial-and-error methods to find compounds that work in the desired way. 
  • Furthermore, the need to have proper infrastructure for the safe handling and safe containment of highly potent drugs, as well as the need for suitable analytical capabilities, particularly for high potency drugs, proper project management (that includes proper induction, running, and completion) highlight the need for R&D in the market.
Pharmaceutical CDMO Market Trends

North America is Estimated to hold the largest market for CMO

  • Contract manufacturing organizations (CMOs) in the United States have evolved from initially providing basic manufacturing services to providing a wide range of services that suit the demand of the market and the outsourcers. The steady growth of the US pharmaceutical industry and increased outsourcing of large pharma companies that are focusing on core competencies to improve profit margins are driving the market in the country.
  • The stricter regulation in the country ensures superior quality of the manufacturing and the end-product that is being adhered to by the CMOs. For instance, the process of manufacturing autologous or allogeneic therapies is complex, and the manufacturing facilities are required to attain a GMP accreditation. 
  • There are more than 800 active Investigational New Drug (IND) waiting for approval from the FDA. This burgeoning approval and drug-developing pipelines are expected to promise more opportunities to CMOs in the future. Nevertheless, many of the drugs approved had orphan designation, which suggests that they are targeted at people with rare diseases. 
  • The pharmaceutical industry of Canada is one of the most innovative in terms of products. Pharmaceutical, a key sector of the Canadian economy, is supported by the Canadian government, which provides a business-friendly environment for pharmaceutical companies and can leverage assets for short- and long-term business strategies. 
  • In the wake of the patent cliffs, pharmaceutical companies in the country are reorganizing and looking for new business models built on third-party partnerships and external networks. This model of business mostly relies on outsourcing most of the operations, including manufacturing, thereby providing good growth opportunities for CMOs in this region.
Pharmaceutical CDMO Market Growth

Competitive Landscape

Although the market studied is highly fragmented, major vendors account for the majority of the market share. The presence of many players in the market studied has an impact on the pricing of services, making it a direct competing factor, especially for small-scale vendors. The vendors in the market studied are expected to focus on providing one-stop-shop services, which would provide them with a competitive advantage. These practices would be possible for the CMOs with access to large capital. This factor increases the competition and acts as a barrier to entry for new players. 

  • March 2022 - Catalent announced a collaboration agreement focused on the generation, testing, and manufacturing of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals' patented Thin Film Freezing (TFF) technology. 
  • February 2022 - Recipharm announced the acquisition of Arranta Bio, a prominent advanced therapy CDMO. The acquisition is a key component of Recipharm's ambition to provide scientifically differentiated contract development and manufacturing services to innovative medication developers in the biologics sector.

Recent Developments

  • March 2022 - Pfizer acquired Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies to treat several immuno-inflammatory diseases. Temanogrel for microvascular blockage, Raynaud's phenomenon secondary to systemic sclerosis, and APD418 for acute heart failure are Arena's cardiovascular assets in development.
  • January 2022 - Idorsia Ltd and Syneos Health announced to extend the existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia, across Europe and Canada.
  • December 2021 - CMIC Co. Ltd and Lokavant, a leading clinical trial intelligence company, announced that they have significantly expanded their enterprise partnership. The new, multi-year partnership puts Lokavant's platform at the core of CMIC's technology and innovation strategy and continues to expand Lokavant's growing presence in APAC. 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET INSIGHTS

    1. 4.1 Market Overview

    2. 4.2 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.2.1 Porter's Five Forces Analysis for CMO

      2. 4.2.2 Porter's Five Forces Analysis for CRO

    3. 4.3 Industry Value Chain Analysis

    4. 4.4 Industry Policies

    5. 4.5 Assessment of the Impact of COVID-19 on Industry

  5. 5. MARKET DYNAMICS

    1. 5.1 Market Drivers

      1. 5.1.1 Increasing Outsourcing Volume by Big Pharmaceutical Companies

      2. 5.1.2 Advent of CDMO Model into the Market

      3. 5.1.3 Increasing Investment in R&D

    2. 5.2 Market Restraints

      1. 5.2.1 IIncreasing Lead Time and Logistics Costs

      2. 5.2.2 Stringent Regulatory Requirements

      3. 5.2.3 Capacity Utilization Issues Affecting the Profitability of CMOs

    3. 5.3 Emphasis on Solid-based Oral Dosage Formulations

    4. 5.4 Qualitative Coverage on the 3D Printing Developments in the OSD Segment

      1. 5.4.1 Evolution of 3D Printing in fabrication processes and the key advantages over conventional processes

      2. 5.4.2 Analysis of major drugs manufactured using 3D printing-based process

      3. 5.4.3 Analysis of key techniques deployed (SLS & FDM) along with their relative advantages

      4. 5.4.4 Key Developments On Stakeholders

      5. 5.4.5 Market Outlook

  6. 6. TECHNOLOGY SNAPSHOT

    1. 6.1 Dosage Formulation Technologies

    2. 6.2 Dosage Forms by Route of Administration

    3. 6.3 Key Considerations for Outsourcing of Pharmaceutical R&D

    4. 6.4 Major Segments in CRO Bio Analytical Testing, Central Laboratory Testing, and cGMP Testing

  7. 7. MARKET SEGMENTATION

    1. 7.1 By Service Type CMO Segment

      1. 7.1.1 Active Pharmaceutical Ingredient (API) Manufacturing

      2. 7.1.2 Finished Dosage Formulation (FDF) Development and Manufacturing

        1. 7.1.2.1 Solid Dose Formulation

        2. 7.1.2.2 Liquid Dose Formulation

        3. 7.1.2.3 Injectable Dose Formulation

      3. 7.1.3 Secondary Packaging

    2. 7.2 By Research Phase CRO Segment

      1. 7.2.1 Pre-clinical

      2. 7.2.2 Phase I

      3. 7.2.3 Phase II

      4. 7.2.4 Phase III

      5. 7.2.5 Phase IV

    3. 7.3 By Geography - Global Pharmaceutical CMO

      1. 7.3.1 North America

        1. 7.3.1.1 Segmentation by Service Type

        2. 7.3.1.2 Segmentation by Country

          1. 7.3.1.2.1 United States

          2. 7.3.1.2.2 Canada

      2. 7.3.2 Europe

        1. 7.3.2.1 Segmentation by Service Type

        2. 7.3.2.2 Segmentation by Country

          1. 7.3.2.2.1 United Kingdom

          2. 7.3.2.2.2 Germany

          3. 7.3.2.2.3 France

          4. 7.3.2.2.4 Italy

          5. 7.3.2.2.5 Rest of Europe

      3. 7.3.3 Asia Pacific

        1. 7.3.3.1 Segmentation by Service Type

        2. 7.3.3.2 Segmentation by Country

          1. 7.3.3.2.1 China

          2. 7.3.3.2.2 India

          3. 7.3.3.2.3 Japan

          4. 7.3.3.2.4 Australia

          5. 7.3.3.2.5 Rest of Asia Pacific

      4. 7.3.4 Latin America

        1. 7.3.4.1 Segmentation by Service Type

        2. 7.3.4.2 Segmentation by Country

          1. 7.3.4.2.1 Brazil

          2. 7.3.4.2.2 Mexico

          3. 7.3.4.2.3 Argentina

          4. 7.3.4.2.4 Rest of Latin America

      5. 7.3.5 Middle East and Africa

        1. 7.3.5.1 Segmentation by Service Type

        2. 7.3.5.2 Segmentation by Country

          1. 7.3.5.2.1 United Arab Emirates

          2. 7.3.5.2.2 Saudi Arabia

          3. 7.3.5.2.3 South Africa

          4. 7.3.5.2.4 Rest of Middle East and Africa

    4. 7.4 By Geography- Global Pharmaceutical CRO

      1. 7.4.1 North America

      2. 7.4.2 Europe

      3. 7.4.3 Asia Pacific

      4. 7.4.4 Latin America

      5. 7.4.5 Middle East and Africa

  8. 8. COMPETITIVE LANDSCAPE*

    1. 8.1 Company Profiles - CMO

      1. 8.1.1 Catalent Inc.

      2. 8.1.2 Recipharm AB

      3. 8.1.3 JUBILANT Life Sciences Ltd

      4. 8.1.4 Patheon Inc.

      5. 8.1.5 Boehringer Ingelheim Group

      6. 8.1.6 Pfizer CentreSource

      7. 8.1.7 Aenova Holding GmbH

      8. 8.1.8 Famar SA

      9. 8.1.9 Baxter Biopharma Solutions

      10. 8.1.10 Lonza Group

      11. 8.1.11 Tesa Labtec GmbH (TESA SE)

      12. 8.1.12 Tapemark

      13. 8.1.13 ARX LLC

    2. 8.2 Company Profiles - CRO

      1. 8.2.1 CMIC Holdings Co. Ltd

      2. 8.2.2 Covance Inc.

      3. 8.2.3 Syneos Health Inc.

      4. 8.2.4 LSK Global Pharma Service Co. Ltd

      5. 8.2.5 Novotech Pty Ltd

      6. 8.2.6 PAREXEL International Corporation

      7. 8.2.7 Pharmaceutical Product Development LLC

      8. 8.2.8 PRA Health Sciences Inc.

      9. 8.2.9 Quanticate Ltd

      10. 8.2.10 IQVIA Holdings Inc.

      11. 8.2.11 SGS Life Science Services SA

      12. 8.2.12 Hangzhou Tigermed Consulting Co. Ltd

      13. 8.2.13 Samsung Bioepis Co. Ltd

      14. 8.2.14 WuXi AppTec Inc.

      15. 8.2.15 Sagimet Biosciences (3V Biosciences Inc.)

  9. 9. INVESTMENT SCENARIO

  10. 10. FUTURE OF THE GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Pharmaceutical CDMO Market market is studied from 2020 - 2027.

The Pharmaceutical CDMO Market is growing at a CAGR of 7.29% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Catalent Inc., Recipharm AB, Jubilant Life Sciences Ltd., Patheon Inc., Boehringer Ingelheim Group are the major companies operating in Pharmaceutical CDMO Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!